November 22, 2024 7:58am
“The Little Engine” that could, a story about reaching difficult goals; the sector can tow investors by their risk appetite
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
MY Pre-Open Thoughts: 1 Positive and 3 Negative Indications
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Thursday’s night’s … RegMed Investors (RMi) Closing Bell: cell and gene therapy sector equities ran the gauntlet through the forest of sentiment increasing its distance to conviction … https://www.regmedinvestors.com/articles/13708
Friday: The pre-open Dow futures are UP +0.01% (+9 points), the S&P futures are DOWN -0.11% or (-6 points) and the Nasdaq futures are DOWN -0.22% or (-45 points)
- Stock futures are falling on Friday, 11/22
- European stocks were higher,
- Asia Pacific markets mostly rise.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Thursday: The Dow closed UP +461.88 points or +1.06%, the S&P closed UP +31.60 points or +0.53% while the Nasdaq closed UP +6.28 points or +0.03%
if the stock market stays up …:
- The Nasdaq is up 1.56% week to date
- The S&P 500 is up 1.33% week to date
- The Dow is up 0.98% week to date.
Economic Data Docket: S&P Global US manufacturing PMI, November preliminary (48 expected, 48.5 previously); S&P Global US services PMI, November preliminary (55 expected, 55 previously); S&P Global US Composite PMI, November preliminary (54.1 previously); University of Michigan consumer sentiment, November final (73 expected, 73 previously)
Q4/24: November 9 negative and 6 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive Indications:
Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed down -$0.91 after Wednesday’s -$0.80, Tuesday’s +$1.17, Monday’s +$0.07 and last Friday’s -$2.26 following the previous Thursday’s -$0.31 and Wednesday’s -$0.44 with a positive +$0.13 or +0.55% aftermarket
Negative Indication:
Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Alnylam Pharmaceuticals (ALNY) closed down -$1.99 after Wednesday’s +$14.52, Tuesday’s +$2.00, Monday’s -$22.35 with a negative -$0.90 or -0.36% pre-market
Mesoblast (MESO) closed down -$0.15 after Wednesday’s -$0.49, Tuesday’s +$0.18, Monday’s +$0.60, and last Friday’s -$1.28 following the previous Thursday’s -$0.39 and Wednesday’s +$1.76 with a negative -$0.08 or -0.79% pre-market
Vericel (VCEL) closed up down -$0.55 after Wednesday’s +$1.43, Tuesday’s +$2.94, Monday’s +$0.41 and last Friday’s +$0.41 with a negative -$1.09 or -1.92% pre-open aftermarket
The BOTTOM LINE: A flip to the switch … an up session after too many down sessions.
Ranking the end of October:
- 11/21 - Thursday: closed positive with 18 incliner, 16 decliners and 1 flat
- 11/20 – Wednesday: closed negative with 15 incliner, 17 decliners and 3 flats
- 11/19 - Tuesday closed positive with 19 incliner, 14 decliners and 2 flats
- 11/18 – Monday closed negative with 14 incliner, 20 decliners and 1 flat
- 11/15 – Friday: closed negative with 4 incliner, 31 decliners and 1 flat
- 11/14 – Thursday: closed negative with 3 incliner, 31 decliners and 1 flat
- 11/13 – Wednesday: closed negative with 8 incliner, 25 decliners and 2 flats
- 11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
- 11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat
- 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
- 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
- 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
- 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
- 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
- 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats
I haven’t changed my tune; it’s time for the oversold to continue to be recognized, one of my calling cards with words!
- A further injection of sentiment mixed with conviction needed.
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
